Literature DB >> 22723595

Potential unmet need for gout diagnosis and treatment: capture-recapture analysis of a national administrative dataset.

Gary Jackson1, Craig Wright, Simon Thornley, William J Taylor, Leanne Te Karu, Peter J Gow, Bruce Arroll, Barry Gribben, Nicola Dalbeth, Doone Winnard.   

Abstract

OBJECTIVE: To estimate the degree of undercount of people diagnosed with gout in administrative datasets using capture-recapture methods.
METHODS: Hospitalization and drug dispensing claims (allopurinol or colchicine) data for all Aotearoa New Zealand were used to estimate the prevalence of gout in 2009 (n = 4 295 296). As a comparison, we calculated gout prevalence using a large primary care dataset using general practitioner diagnosis and prescribing records (n = 555 313). For each of these datasets, we estimated the undercount through capture-recapture analysis using a Poisson regression model. A two-list model was used, which included covariates such as age, gender, ethnic groups and New Zealand deprivation quintiles.
RESULTS: The crude prevalence of diagnosed gout in the Aotearoa New Zealand population aged ≥ 20 years was 3.75%. The covariate-adjusted capture-recapture estimate of those not recorded but likely to have gout was 0.92%, giving an overall estimated prevalence of 4.67% (95% CI 4.49, 4.90%) for the population aged ≥ 20 years. This amounts to 80% of people with gout being identified by the algorithm for the Aotearoa New Zealand data-that is being recorded in either lists of dispensing of allopurinol or colchicine or hospital discharge. After capture-recapture, gout prevalence for all males aged ≥ 20 years was 7.3% and in older (≥ 65 years) Māori and Pacific men was >30%.
CONCLUSION: Capture-recapture analysis of administrative datasets provides a readily available method for estimating an aspect of unmet need in the population-in this instance potentially 20% of those with gout not being identified and treated specifically for this condition.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22723595     DOI: 10.1093/rheumatology/kes147

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

Review 1.  Imaging in gout: A review of the recent developments.

Authors:  Priya Varghese Chowalloor; Teck K Siew; Helen Isobel Keen
Journal:  Ther Adv Musculoskelet Dis       Date:  2014-08       Impact factor: 5.346

2.  Allopurinol use in a New Zealand population: prevalence and adherence.

Authors:  Simon Horsburgh; Pauline Norris; Gordon Becket; Bruce Arroll; Peter Crampton; Jacqueline Cumming; Shirley Keown; Peter Herbison
Journal:  Rheumatol Int       Date:  2014-01-04       Impact factor: 2.631

Review 3.  Screening for hyperuricaemia and gout: a perspective and research agenda.

Authors:  Lisa Stamp; Nicola Dalbeth
Journal:  Nat Rev Rheumatol       Date:  2014-08-19       Impact factor: 20.543

4.  The experience and impact of gout in Māori and Pacific people: a prospective observational study.

Authors:  Nicola Dalbeth; Meaghan E House; Anne Horne; Leanne Te Karu; Keith J Petrie; Fiona M McQueen; William J Taylor
Journal:  Clin Rheumatol       Date:  2012-11-01       Impact factor: 2.980

5.  Estimating human leishmaniasis burden in Spain using the capture-recapture method, 2016-2017.

Authors:  Ana María Humanes-Navarro; Zaida Herrador; Lidia Redondo; Israel Cruz; Beatriz Fernández-Martínez
Journal:  PLoS One       Date:  2021-10-29       Impact factor: 3.240

6.  Lack of change in urate deposition by dual-energy computed tomography among clinically stable patients with long-standing tophaceous gout: a prospective longitudinal study.

Authors:  Ashwin Rajan; Opetaia Aati; Ramanamma Kalluru; Gregory D Gamble; Anne Horne; Anthony J Doyle; Fiona M McQueen; Nicola Dalbeth
Journal:  Arthritis Res Ther       Date:  2013-10-23       Impact factor: 5.156

7.  Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Christian Mallen; Weiya Zhang; Michael Doherty
Journal:  Ann Rheum Dis       Date:  2014-01-15       Impact factor: 19.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.